Related Experiment Videos
BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood
A Dzionek1, A Fuchs, P Schmidt
1Miltenyi Biotec GmbH, Bergisch Gladbach, Germany. AmCell Corporation, Sunnyvale, CA 94089, USA.
Insights
Researchers identified three new human dendritic cell antigens: BDCA-2, BDCA-3, and BDCA-4. These antigens serve as specific markers for distinct dendritic cell subsets in blood, aiding further analysis and therapeutic evaluation.
Area of Science:
- Immunology
- Cell Biology
- Hematology
Background:
- Dendritic cells (DCs) are crucial immune regulators.
- Specific markers are needed to distinguish human blood dendritic cell subsets.
- Novel antigens can advance the study of dendritic cell populations.
Purpose of the Study:
- To generate and characterize monoclonal antibodies (mAbs) against novel human dendritic cell antigens.
- To identify specific markers for distinct dendritic cell subpopulations in human blood.
- To investigate the expression patterns of these antigens during dendritic cell maturation.
Main Methods:
- Generation of a panel of monoclonal antibodies (mAbs).
- Immunophenotypic analysis of human blood dendritic cell subsets using flow cytometry.
- Assessment of antigen expression on immature and in vitro matured dendritic cells.
Main Results:
- Three presumably novel antigens, BDCA-2, BDCA-3, and BDCA-4, were identified.
- BDCA-2 and BDCA-4 mark plasmacytoid DCs, while BDCA-3 marks a distinct CD11c(+) subset.
- Antigen expression changes significantly upon in vitro maturation, with BDCA-2 down-regulated and BDCA-3/BDCA-4 up-regulated.
Conclusions:
- BDCA-2, BDCA-3, and BDCA-4 are specific markers for human blood dendritic cell subpopulations.
- These novel antigens are valuable tools for analyzing dendritic cell subsets in fresh blood.
- The identified markers will facilitate further research into the therapeutic potential of dendritic cells.
Abstract:
We have generated a panel of mAbs that identify three presumably novel human dendritic cell Ags: BDCA-2, BDCA-3, and BDCA-4. In blood, BDCA-2 and BDCA-4 are expressed on CD11c(-) CD123(bright) plasmacytoid dendritic cells, whereas BDCA-3 is expressed on small population of CD11c(+) CD123(-) dendritic cells. All three Ags are not detectable on a third blood dendritic cell population, which is CD1c(+) CD11c(bright) CD123(dim), or on any other cells in blood. BDCA-4 is also expressed on monocyte-derived and CD34(+) cell-derived dendritic cells. Expression of all three Ags dramatically changes once blood dendritic cells undergo in vitro maturation. BDCA-2 is completely down-regulated on plasmacytoid CD11c(-) CD123(bright) dendritic cells, expression of BDCA-3 is up-regulated on both plasmacytoid CD11c(-) CD123(bright) dendritic cells and CD1c(+) CD11c(bright) CD123(dim) dendritic cells, and expression of BDCA-4 is up-regulated on CD1c(+) CD11c(bright) CD123(dim) dendritic cells. BDCA-2 is rapidly internalized at 37 degrees C after mAb labeling. The three presumably novel Ags serve as specific markers for the respective subpopulations of blood dendritic cells in fresh blood and will be of great value for their further analysis and to evaluate their therapeutic potential.